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Abstract: The aim of the present study is preparation of mannosylated liposomes with built-in small molecule immunopotentiators for targeted, 
receptors mediated, delivery of antigens. The liposomes were mannosylated in two ways, by covalent attachment of p-aminophenyl-α-D-
mannopyranoside to the preformed liposomes and by incorporation of synthetic mono-, di- and tetramannosyl-lipoconjugates into the lipid 
bilayer of liposomes. Four different mannosylated liposome formulations with incorporated model antigen, ovalbumin (OVA), and immuno-
modulators, PGM and Ad2TP2, were prepared and characterized. The influence of mannosylated liposome formulations on the antigen-specific 
humoral immune response was investigated. It has been shown that mannosylated liposomal formulations did not enhance the humoral 
immune response and production of anti-OVA antibodies but they significantly affected the type of OVA specific immune reaction and directed 
it towards Th1 type. 
 





ODERN vaccine development in the 21st century is 
based on the recombinant subunit strategy.[1–3] Sub-
unit vaccines contain selected antigens that carry specific 
pathogen epitopes necessary for efficacious anti-pathogen 
specific immune response. The problem with highly purified 
recombinant proteins or synthetic antigens used, is their 
lower immunogenicity in comparison with attenuated or 
killed whole organism in conventional vaccine formula-
tions.[4] In order to overcome low immunogenicity, powerful 
adjuvants are being developed.[5,6] The liposomes are recog-
nized as excellent drug (or antigen) delivery vehicles since 
they are biocompatible, nontoxic, biodegradable and capa-
ble of site-specific drug delivery.[7] Liposomes with built-in 
small molecule immunopotentiators represent potent adju-
vant formulations which can transport the antigen from the 
injection site to the lymphoid tissue, ensure protection of an-
tigen from the action of hydrolytic enzyme as well as to 
enhance production of specific cytokines and augment the 
immune response.[8,9] Mannosylated liposomes have been 
considered particularly attractive drug delivery carriers be-
cause of their ability to target mannose receptors (MR), 
which have very important role in a large variety of cellular 
processes.[10,11] MRs expressed on macrophages and antigen 
presenting cells, APCs mediate endocytosis and actively co-
operate in antigen capture and presentation. MRs recognize 
carbohydrate moieties of many pathogens therefore target-
ing of glycosylated antigens or carrier systems to MRs is a 
method to enhance vaccine or drug activity.[12] MRs specifi-
cally recognize terminal mannose, fucose and N-acetylglucos-
amine carbohydrate.[13,14] Carbohydrate–protein inter-
actions between individual monosaccharide units (ligands) 
and protein (receptor) are usually weak in affinities but it can 
be overcome throught multivalency. The enhanced binding 
affinity resulting from simultaneous interaction of multiple 
determinant sugar residues with several binding sites of a 
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 Various strategies have been developed to achive 
adequate surface decoration of liposomes with the man-
nose ligands in order to obtain efficient recognition by 
MRs.[17] It was shown that mannose density on the surface 
of liposomes as well as stereochemical arrangement of 
mannosyl epitopes, valency and type of linker used, signifi-
cantly affect recognition and binding by MRs.[18–20] Efficiency 
of mannosylated liposomes in targeted drug delivery has 
been demonstrated in numerous studies.[21–27] Our previous 
studies have been focused on the synthesis of novel im-
munomodulators and potent adjuvant formulations with 
improved activity.[28–30] In recently published paper we de-
scribed the synthesis of mono-, di- and tetramannosyl-
lipoconjugate, used for mannosylation of liposomes, and 
studies of interaction of prepared mannosylated liposomes 
with model lectine, concanavaline A (Con A) by quartz crys-
tal microbalance (QCM).[31]  
 Here we report preparation of mannosylated lipo-
somes with built-in peptidoglycan based immunomodula-
tors, peptidoglycan monomer (β-D-GlcNAc-(1→4)-D-MurNAc-
L-Ala-D-isoGln-mesoDAP(εNH2)-D-Ala-D-Ala, PGM), adamant-
yltripeptide L-(adamant-2-yl)-Gly-L-Ala-D-isoGln (Ad2TP2) 
(Figure 1), and ovalbumin (OVA) as a model antigen. 
Previously synthesized mono-, di- and tetramannosyl-
lipoconjugates (Figure 2) were incorporated into lipid 
bilayer. Additionally, in order to compare different ways of 
liposome mannosylation to their in vivo effect, preformed 
liposomes were mannosylated by covalent attachment  
of p-aminophenyl-α-D-mannopyranoside on liposomes’ 
surface. Mannosylated liposome formulations of antigen 
with built-in immunomodulators were characterized and 
their adjuvant effect was tested. Furthermore, the ability of 
liposome formulations with structuraly different mannosyl 
ligands on the surface, to modulate production of total 




Materials and Methods 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino-
(polyethylene glycol)-2000] (ammonium salt) (DSPE-PEG-
NH2) and L-α-phosphatidylcholine, type XI-E: from fresh egg 
yolk (egg-PC) were from Avanti Polar Lipids. Cholesterol 
from porcine liver, p-aminophenyl-α-D-mannopyranoside, 
2,4,6-trinitrobenzene sulfonic acid (TNBSA), o-phenylene-
diamine dihydrochloride (OPD), bovine serum albumin 
(BSA), Tween 20, monoclonal anti-chicken egg albumin 













































Figure 1. The chemical structures of peptidoglycan monomer (β-D-GlcNAc-(1→4)-D-MurNAc-L-Ala-D-isoGln-mesoDAP(εNH2)-D-
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were obtained from Sigma-Aldrich. Ovalbumin (OVA) was 
purchased from Serva. Horseradish peroxidase conjugated 
goat anti-mouse IgG (HRP-anti-mouse IgG) was from BioRad 
Laboratories. Biotin-conjugated rat anti-mouse IgG1 and 
anti-mouse IgG2a monoclonal antibodies and streptavidin-
peroxidase were purchased from BD PharMingen. 
 Acetonitrile and trifluoroacetic acid (TFA) were of 
HPLC grade from Merck (Darmstadt, Germany). A daily sup-
ply of water was obtained from Millipore Simplicity–Per-
sonal ultra-pure water system (Bedford, MA, USA).  
 Chemicals for buffers and solutions were from 
Kemika, unless stated otherwise. Peptidoglycan monomer 
(PGM) was prepared in PLIVA, Chemical and Pharmaceuti-
cal Works (Zagreb, Croatia), according to the previously de-
scribed procedure.[32] L-(adamant-2-yl)glycyl-L-alanyl-D-
isoglutamine (Ad2TP2) was prepared at the Institute of Im-
munology (Zagreb, Croatia), as described earlier.[33] Mono-
valent, 1, divalent, 2, and tetravalent, 3, mannosyl-
lipoconjugates were prepared as previously described 
(Figure 2).[31] 
 Chromatographic analysis were carried out using the 
Waters HPLC System equipped with 2996 PDA detector and 
Empower software (Milford, MA, USA). LiChrosorb RP-18  
(5 μm), 4 × 250 mm (Merck) and TSK-gel G300SW 7,5 mm × 60 
cm (Tosoh Biosciences), columns for HPLC analyses were used. 
Preparation of Mannosylated  
Liposomes Formulations 
Multilamellar liposomes were prepared by thin lipid films 
following previously described methods.[31,34] Briefly, egg-
phosphatidylcholine, cholesterol and mannosyl-lypoconju-
gates (1, 2 or 3) in a molar ratio of 7 : 5 : 0,5 were dissolved 
in chloroform : methanol (2 : 1). The chloroform and meth-
anol were evaporated to dryness under vacuum on a rotary 
evaporator, and then lipid film was hydrated with OVA in 
saline, concentration 1 mg/mL by gentle hand shaking. The 
concentration of amphiphiles in liposome suspension was 
4 mg/mL. For incorporation PGM or Ad2TP2 into liposomes, 
the methanol solution of PGM or ethanol solution of 
Ad2TP2 was added to the lipid solution. The concentration 
of immunomodulators, PGM and Ad2TP2, in liposome sus-
pension was 5 mg/mL. The liposome suspension was left 
overnight at 4 °C to swell and stabilize. Liposomes were 
separated from non-encapsulated material by ultracentrif-
ugation. The liposome suspensions were placed into poly-
carbonate centrifugation tubes and centrifuged in the 
ultracentrifuge (Beckman model L5-65, Beckman Coulter 
TM, USA) for 1 h at 55 000 × g. After centrifugation the su-
pernatants were separated from the pellets and submitted 
to HPLC analysis. The pellets were resuspended in saline 
and used for further investigations. Liposome size was re-
duced by repeated extrusion through polycarbonate mem-
branes with the pore size of 800 and 200 nm using the 0,5 
mL extruder (LiposoFast, Avestin Inc., Canada).  
 Liposomes were prepared under sterile conditions, 
using sterile glassware and saline while chemicals and sol-
vents were of high purity. 
Mannosylation of Preformed Liposomes with 
p-Aminophenyl-α-D-Mannopyranoside 
Preformed liposomes were mannosylated by covalent 
attachment of p-aminophenyl-α-D-mannopyranoside to 
DSPE-PEG2000-NH2 of the liposomes using glutaraldehyde 
as a coupling agent following previously described 
method.[35] Briefly, prepared phosphatidylcholine, choles-
terol and DSPE-PEG2000-NH2 liposomes in a molar ratio of 
7 : 5 : 0,5 (4 mg/mL) with encapsulated antigen and im-
munomodulators was mixed with p-aminophenyl-α-D-
mannopyranoside (10 equivalent of DSPE-PEG2000-NH2) 
and 20 % solution of glutaraldehyde (140 equivalent). Sus-
pensions were mixed 5 min and then mannosylated lipo-
some suspensions were separeted from uncoupled p-
aminophenyl-α-D-mannopyranoside and glutaraldehyde by 





























































































































648 A. ŠTIMAC et al.: Mannosylated Liposomes with Built-in Peptidoglycan Based Immunomodulators … 
 




into polycarbonate centrifugation tubes and centrifuged in 
the ultracentrifuge (Beckman model L5-65, Beckman 
Coulter TM, USA) for 1 h at 55 000 × g. After centrifugation 
the supernatants were separated from the pellets and the 
pellets were resuspended in saline. The liposome sus-
pensions were extruded through polycarbonate mem-
branes with the pore size of 800 and 200 nm using the 0,5 
mL extruder. 
 To estimate the coupling efficiency of p-aminophe-
nyl-α-D-mannopyranoside, the uncoupled amino groups of 
DSPE-PEG2000-NH2 on the liposomes were measured spec-
trophotometrically as described in literature.[35] 100 μL of 4 
% NaHCO3 and 100 μL 10 % SDS were added to 100 μL lipo-
some suspension coupled (or uncoupled) with p-aminophe-
nyl-α-D-mannopyranoside. The liposome suspension was 
incubated at 30 °C and after 20 min 100 μL 0,1 % TNBSA 
solution was added. The resulting solution was kept at 40 ° 
C for 2 h. The reaction was terminated by adding 50 μL of 1 
M HCl. The absorbance of the final solution was read at 335 
nm against blank sample prepared as above with 100 μL of 
saline instead of the liposome suspensions. The coupling ef-
ficiency (CE) was calculated indirectly in accordance to the 
formula, CE = (1 – Auncoupled / Atotal ) × 100 %, where the CE 
is the coupling efficiency of p-aminophenyl-α-D-mannopyra-
noside, Auncoupled is absorbance of uncoupled amino groups 
of DSPE-PEG2000-NH2 on the liposomes after mannosyla-
tion with p-aminophenyl-α-D-mannopyranoside and Atotal is 
the absorbance of amino groups of DSPE-PEG2000-NH2 on 
the liposomes prior to conjugation with p-aminophenyl-α-
D-mannopyranoside.  
Determination of the  
Entrapment Efficiency 
The entrapment efficiency of OVA, PGM and Ad2TP2 in 
mannosylated liposomes was determined by HPLC in the 
supernatants following ultracentrifugation, as described 
previously.[36,37] All analyses were performed at a flow rate 
of 1,0 mL/min at room temperature. The eluate of OVA was 
monitored at 280 nm and eluates of PGM and Ad2TP2 were 
monitored at 214 nm.[38] The isocratic system A was 0,1 M 
phosphate buffer with 0,1 M sulphate buffer and 0,05 % 
NaN3, pH = 6,6, prepared with an ultra pure water (daily 
supplied from a Simplicity – Personal ultra pure water 
system, Millipore, USA). Two gradient systems were used 
for the tested compounds. The gradient solvent systems 
used were made of acetonitrile containing 0,035 % TFA and 
water containing 0,05 % TFA. Each system contained a 
different percentage of acetonitrile and the amount of 
acetonitrile was changed at the indicated running times. 
For system B with a running time 25 min, the percentage of 
acetonitrile at 0, 20 and 25 min was 3, 17 and 3, respec-
tively. For system C with running time 20 min, the percent-
age of acetonitrile at 0, 15 and 20 min was 10, 30 and 10, 
respectively. System A was used for analyses of OVA, sys-
tem B for analyses of PGM and system C for analyses 
Ad2TP2. Samples (100 μL OVA, 50 μL PGM and 20 μL 
Ad2TP2) were injected onto column using autosampler. The 
standard curves of tested compounds were constructed for 
each compound prior to the analyses of supernatants from 
the liposome preparations. The amounts of the nonen-
trapped compounds were determined using standard curve 
and the amounts of the entrapped compounds was calcu-
lated by subtracting the obtained value from the total 
amount of the compound used for liposome preparation. 
In vivo Testing of  
Immunostimulating Activity  
All experiments were carried out using NIH/OlaHsd female 
adult mice. During the experimental period animals were 
housed in the Animal Facility of the Institute of Immunology. 
Food and water were provided ad libitum. All animal work 
was performed in line with a national legislative of animal 
welfare (NN 135/06). Animals were immunized and boosted 
two times at 21-days intervals. Mice were anaesthetized with 
i.p. application of ketamine/xylazine (25 mg/kg each) and 
blood was collected from axillary's plexus on the 7th day after 
second booster. Individual sera were decomplemented at  
56 °C for 30 min and stored at –20 °C until tested. Mice were 
immunized subcutaneously in the tail base with 0,1 mL (10 
μg OVA) of appropriate immunisation solution. The amount 
of lipids administered to each mouse was 400 μg.  
ELISA for Qualitative and Quantitative 
Determination of Anti-OVA IgG 
Anti-OVA antibodies were determined by previously de-
scribed ELISA modified as follows.[36,39] Flat-bottomed high 
binding ELISA plates (Costar, USA) were coated with 100 μL 
of 15 μg/mL OVA solution in carbonate buffer, pH = 9,2, 
overnight at room temperature (RT). Non-specific antibody 
binding was blocked by incubation with 0,5 % (w/v) BSA in 
PBS–T (0,05 % (v/v) Tween 20 in PBS) buffer (200 μL per 
well) for 2 h at 37 °C. Standard antibody preparation and 
mouse sera to be tested (100 μL per well) were added in 
serial two-fold dilutions and incubated overnight at RT. All 
samples were analysed in duplicates. Plates were washed 
and 100 μL of goat HRP–anti-mouse IgG (4 000 × diluted) 
was added and incubated 2 h at 37 °C. After washing, the 
substrate solution consisting of 0,6 mg/mL OPD solution in 
citrate–phosphate buffer, pH = 5,0, with 0,5 μL 30 % H2O2 
/mL was added (100 μL per well) and incubated for 30 min 
at RT in the dark. The enzymatic reaction was stopped with 
50 μL per well 12,5 % H2SO4 and absorbency at 492 nm was 
measured using a microplate reader (Reader 530; Organon 
Teknika, The Netherlands). All washings (three times after 
each step) were done with PBS–T buffer in microplate 
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 Quantitative determination of anti-OVA IgGs was 
done by parallel line analysis comparing each serum to the 
standard - monoclonal anti-OVA IgG, to which we voluntar-
ily assigned 20 000 arbitrary units per mL (AU/mL).  
 For quantification of OVA specific immunoglobulin G 
subclass, IgG1 and IgG2a, plates were coated with OVA as 
described above and incubated with sera and standard an-
tibody preparations (IgG1 or IgG2a). Plates were washed 
and 100 μL of biotinylated rat anti-mouse IgG1 at 0,05 
μg/mL or biotinylated rat anti-mouse IgG2a at 0,5 μg/mL 
were added to each well and incubated 2 h at 37 °C. After 
washing, avidin-HRP (50 000 × diluted) was added for de-
termination of IgG1, while streptavidin-HRP (100 000 × di-
luted) was used for IgG2a determination (100 μL per well) 
and incubated 2 h at 37 °C. Plates were washed and sub-
strate solution was added as describe above. The enzymatic 
reaction was stopped with 12,5 % H2SO4 and absorbency at 
492 nm was measured using a microplate reader. 
 The relative quantities of antibody subtypes were 
determined by parallel line assay using appropriate stand-
ard preparation. The monoclonal anti-OVA IgG1 was a 
standard for relative quantification of anti-OVA IgG1 to 
which 400 000 AU/mL was assigned, while polyclonal 
mouse serum containing high levels of anti-OVA IgG2a was 
used as a standard for relative quantification of IgG2a spe-
cific antibodies with voluntarily assigned 5 000 AU/mL. 
Statistical Analysis 
Statistical analyses were performed using Statistica 6.0 for 
Windows, StatSoft Inc. The significant difference between 
experimental groups was determined by Mann-Whitney U-
nonparametric tests. Probability values less than 0,05 (p < 
0,05) were considered significant. 
 
RESULTS AND DISCUSSION 
Preparation of Mannosylated Liposomes 
Mannosylated liposomes have been studied as promising 
carriers for targeted drug delivery because of their ability 
to target MRs, which are considered to be pattern-recog-
nition receptors.[12,40] The glycosylation as well as manno-
sylation of liposome surface can be accomplished in se-
veral ways.[17] The most used methods encompasses 
adsorption of different glycopolimers or a chemical reac-
tion between the glycosylconjugate and liposome.[41] Alt-
hough simple, these methods are constrained regarding 
the stability of liposomes in the reaction mixture. Incor-
poration of synthesized glycosyl lipoconjugates into lipid 
bilayer is the most elegant but also the most challenging 
method. Chemical synthesis, purification and characteri-
zation of such amphiphilic compounds is a very complex 
process.[17] Synthesis of new glycosyl lipoconjugates 
provides many advantages with respect to the design of 
carbohydrate ligands having specific structural character-
istics and their binding on different lipophilic anchors 
such as fatty acids[31] and cholesterol.[42] In our previous 
research, we have shown how adamantane can be used 
as a membrane anchor in lipid bilayer for different car-
bohydrate molecules which are exposed on liposome sur-
face.[30,43] The obtained results have confirmed that Con 
A successfully recognized mannosyl ligands exposed on 
liposome surface and exhibits higher affinity to multi-
valent mannosyl ligands.[31] 
 Here, we report preparation and characterization 
of mannosylated liposomes with/without built-in pepti-
doglycan based immunomodulators, PGM or Ad2TP2, and 
with entrapped model antigen, ovalbumin. The mannosyl-
ated liposomes were prepared in two ways, by incorpora-
tion of synthetic mono-, di- and tetramannosyl-lipoconj-
ugates (1, 2, 3) into the lipid bilayer of liposomes or by 
covalent attachment of p-aminophenyl-α-D-mannopyran-
oside to the preformed liposomes. Immunomodulators 
were incorporated into multilamellar large liposomes 
bearing structurally different mono- and multimannosyl-
ligands on the surface using modified film method. Etha-
nol/methanol solutions of PGM or Ad2TP2 were added 
into organic phase together with phospholipids and man-
nosyl-lipoconjugate and prepared thin lipid films were hy-
drated with 1 mg/mL OVA in saline. 
 Post-modification of preformed liposomes was car-
ried out by covalent attachment of p-aminophenyl-α-D-
mannopyranoside to DSPE-PEG2000-NH2 incorporated in 
liposomes made of phosphatidylcholine : cholesterol : 
DSPE-PEG2000-NH2 = 7 : 5 : 0,5 using glutaraldehyde as 
the coupling agent in accordance with the previously pub-
lished procedure[35] (Figure 3). Excessive amount of glu-
taraldehyde and p-aminophenyl-α-D-mannopyranoside 
after chemical reactions were removed by ultracentrifu-
gation. Coupling efficiency of p-aminophenyl-α-D-manno-
pyranoside and liposome was measured spectrophoto-
metrically by adding the visualization reagent, TNBSA. The 
calculated coupling efficiencies of p-aminophenyl-α-D-
mannopyranoside and preformed liposomes are pres-
ented in Table 1. 
 Coupling efficiency of p-aminophenyl-α-D-manno-
pyranoside on empty liposomes and liposomes with encap-
sulated OVA were 28,06 and 28,73 % respectively, and are 
in accordance with the published data.[35] It was demon-
strated that OVA did not affect the coupling efficiency of  
p-aminophenyl-α-D-mannopyranoside and preformed lipo-
somes. Increase in coupling efficiency was observed for 
liposomes with entrapped PGM and particularly for liposom-
es with entrapped Ad2TP2. A possible explanation lies in the 
abovementioned ability of adamantane to accommodate 
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is exposed on liposome surface. While Ad2TP2 can be 
entrapped in the aqueos phase of liposomes, it is also 
partialy incorporated in lipid bilayer of liposomes.[44] The 
peptide part of Ad2TP2 is near the liposome surface and its 
free amino group is available for reaction with glutar-
aldehyde and p-aminophenyl-α-D-mannopyranoside. Since 
the PGM is a hydrophilic molecule and is not embedded in 
the lipid bilayer of a liposome we presume that PGM could 
be non-specifically adsorbed on hydrophylic polyethylene 
glycol in DSPE-PEG2000-NH2 molecule incorporated in 
liposome bilayer. PGM possesses a reactive amino group on 
diaminopimelic acid in the peptide part of the molecule 
that could react with glutaraldehyde and thus potentiate 
the binding of p-aminophenyl-α-D-mannopyranoside. The 
obtained results have confirmed that covalent attachment 
of p-aminophenyl-α-D-mannopyranoside to preformed lipo-
some has successfully conducted with high coupling 
efficiency. 
Determination of the Entrapment 
Efficiency of OVA and 
Immunomodulators, PGM and Ad2TP2 
In order to perform in vivo evaluation of prepared manno-
sylated liposome formulations, it is necessary to determine 
the entrapment efficiency of antigen and built-in immuno-
modulators. The entrapment efficiency of OVA, PGM and 
Ad2TP2 in mannosylated liposomes was determined in ac-
cordance with previously developed methods.[34,36] The re-
sults of entrapment efficiency of OVA, PGM and Ad2TP2 
into mannosylated liposomes are presented in Table 2. 
 It was shown that the entrapment efficiency for 
OVA and immunomodulators is highest in preformed 
liposomes which underwent post-modification by 
covalent attachment of p-aminophenyl-α-D-mannopyr-
anoside. The entrapment efficiency of OVA, PGM and 
Ad2TP2, is about 30 % in preformed mannosylated 
liposomes and it is in accordance with the method and 
buffer used. Previously, we have shown that the amount 
of OVA, PGM and Ad2TP2 entrapped into non-
mannosylated liposomes mostly depends on the ionic 

















































hydrophobic tails of DSPE-PEG2000-
NH2 inserted into lipid bilayer
 
Figure 3. Post-modification of preformed liposomes and covalent attachment of p-aminophenyl-α-D-mannopyranoside to the 
DSPE-PEG2000-NH2 in MLV liposomes. 
 
Table 1. Coupling efficiency of p-aminophenyl-α-D-
mannopyranoside and preformed liposomes. The results 
are expressed as an average value ± standard deviation of 
three different liposome preparations in duplicates 
Sample Coupling efficiency / % 
Empty liposomes  28,06 ± 4,77 
Liposomes with OVA   28,73 ± 9,83 
Liposomes with OVA  + PGM  41,24 ± 6,49 
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 The amount of OVA, PGM and Ad2TP2 entrapped 
into mannosylated liposomes containing PC and choles-
terol together with mono-, di- and tetra mannosyl-lipocon-
jugates varies greatly. Synthesized mannosyl-lipoconjug-
ates containing DSPE-PEG2000-NH2 and branched carbo-
hydrate ligand bound to the linker, are very complex 
molecules and they strongly affect the formation of lipid 
bilayer of liposomes and incorporation of compounds into 
liposomes. The increase of number of mannose molecules 
in di- and tetramannosyl-lipoconjugate, incorporated into 
liposomes causes increased branching of bulky moieties on 
the inner and outer sides of liposome leaflets. Conseq-
uently, the entrapped aqueous volume with examined 
compounds is smaller, resulting in the decrease of 
entrapment efficiency of OVA, PGM and Ad2TP2 into di- and 
tetramannosylated liposomes in comparison with entrap-
ment efficiency into preformed monomannosylated lipo-
somes. Therefore, entrapment of compounds into tetra-
mannosylated liposomes was lowest because of multi-
valency and branching of mannose residues of tetra-
mannosyl-lipoconjugate 3 incorporated into lipid bilayer of 
liposomes. It is known that incorporation of DSPE-PEG into 
liposomes reduces the internal aqueous volume by bulky 
PEG chains which cover inner and outer liposome leaflets, 
resulting in the decrease of entrapment efficiency.[45,46] The 
influence of bulky multivalent mannosyl lipoconjugates on 
incorporation, is best exemplified Ad2TP2, where the incor-
poration efficiency is decreased in dimannosylated and par-
ticularly in tetramannosylated liposomes compared with 
monomannosylated liposomes. The amount of entrapped 
Ad2TP2 is the highest in the monomannosylated preformed 
liposomes and lowest in tetramannosylated liposomes 
since the adamantane except to the aqueous phase can 
also be incorporated into the lipid bilayer. The decrease of 
entrapment efficieny of OVA and PGM in di- and tetraman-
nosylated liposomes compared with monomannosylated 
preformed liposomes is also observed. Here, the entrap-
ment efficiency of OVA into monomannosylated liposomes 
containing monomannosyl-lipoconjugate, Man-PEG-pal-
mitamide 1 is the lowest. This result can be explained  
by electrostatic repulsion of amphiphile and OVA during 
rehydratation of lipid film and liposome formation. OVA is 
negatively charged at pH = 7.4 (pI = 4.6).[31] PC-liposomes at 
pH = 7,4 have slightly negative charge and PEGylation of 
liposomes decreases the zeta potential because a hydro-
philic coat on the surface of liposomes is formed. Incor-
poration of Man-PEG-palmitamide 1, into lipid bilayer 
causes less shading of negative charge due to smaller size 
of the polymer chain of PEG molecule in comparison with 
PEG molecule in tetramannosyl conjugate, as we have 
shown previously.[31] 
The Influence of Different Mannosylated 
Liposome Formulations of OVA and 
Immunomodulators on Anti-OVA 
Immune Response in vivo 
Adjuvant property of liposomes was first reported in 
1974[47] and since then the liposomes have been intensively 
studied in terms of delivery of different antigens.[43,44] 
Liposomes can be excellent antigen carriers and adjuvants 
of a new generation due to their biocompatibility and their 
physicochemical properties which can be tailored to obtain 
different immunological effects. The binding of specific 
ligands at liposome surface for targeted pathogen recog-
nition receptors (PRRs) is one of the convenient ways to 
activate the entire immune response. PRRs are molecules 
on cell surface that recognize pathogens and can affect the 
strength and direction of the immune response.[48,49] MRs 
are group of PRRs molecules and C-type lectins which are 
expressed in mice and humans and show mannose–binding 
ability but their role in host defence is still not clearly 
understood. The participation of MRs in phagocytosis, 
antigen presentation and intracellular signalling have been 
shown.[50,51] This explains why the design and synthesis of a 
new drug delivery systems using mannosyl ligands for 
targeting MRs represents a promising model to achieve 
strong and specific immune response.[10]  
 In present study, we have prepared mannosylated 
liposomes with built-in small molecule immunopotentia-
tors, PGM and Ad2TP2, for targeted delivery of OVA antigen 
and evaluated their influence on production of specific anti-
OVA IgGs, particularly IgG subclasses. Increased production 
Table 2. Entrapment efficiency of OVA, PGM and Ad2TP2 in mannosylated liposomes. The results are expressed as an average 
value ± standard deviation of three different liposome preparations in duplicates 
Sample 
Entrapment efficiency / % 
OVA PGM Ad2TP2 
Preformed monomannosylated liposomes 36,46 ± 7,42 31,30 ± 6,49 36,00 ± 9,34 
Monomannosylated liposomes 8,24 ± 2,07 19,05 ± 9,26 27,22 ±8,32 
Dimannosylated liposomes 27,18 ± 7,42 25,31 ± 3,84 16,30 ± 0,71 
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of IgG2a in mice is an indicator of activation of a Th1 im-
mune response and the ratio IgG1/IgG2a can be used as an 
indirect marker for Th type of immune response.[52] Our 
study addressed the effects of mannose valency of synthe-
sized ligands exposed on the liposome surface, on the 
recognition by MRs as well as effects of prepared liposome 
formulations on the specific anti-OVA immune response. 
Adjuvant activity of mannosylated liposome formulations 
in vivo, was evaluated in NIH/OlaHsd mice according to our 
previously described procedure.[36,39] OVA was chosen as an 
antigen of low immunogenicity in accordance with recom-
mendations for adjuvant testing.[53] Production of total anti-
OVA IgG, as well as anti-OVA IgG1 and anti-OVA IgG2a sub-
classes was determined by ELISA in the mice sera after the 
second booster. The parallel line assay using appropriate 
standard antibody preparation for relative quantities of an-
tibodies determination was used. Results are expressed in 
arbitrary units per milliliter (AU/mL). Results of total anti-
OVA IgG production in mice immunized with mono-, di- and 
tetramannosylated liposome formulations with OVA and 
immunomodulators, are presented in a box-and-whisker 
plot in Figure 4. Encapsulation of OVA into mannosylated 
liposomes overall decreased the amount of produced spe-
cific IgGs in comparison with amount of IgGs produced in 
experimental group of mice where antigen was applied in 
saline. Incorporation of PGM and Ad2TP2 in mannosylated 
liposomes did not significantly affect the total anti-OVA IgG 
production in comparison to mannosylated liposomes with 
antigen alone with the exception of dimannosylated lipo-
somes. The possible explanation could be low OVA availa-
bility since significantly lower entrapment of OVA, PGM and 
Ad2TP2 into mannosylated liposomes was observed (Table 2). 
 Adjuvants can express their activity through several 
mechanisms of action: the depot effect, increased antigen 
presentation effect, antigen targeting effect, immunomod-
ulation effect and CTL induction effect.[54] As we mentioned 
above, adjuvants can modulate the Th1/Th2 ratio of in-
duced immune response.[55,56] In order to investigate how 
the incorporation of OVA, PGM and Ad2TP2 into mannosyl-
ated liposome can modulate Th type of specific immune re-
sponse, the levels of antibody subclasses were tested. The 
amounts of specific anti-OVA IgG1 and anti-OVA IgG2a, in-
dicators of Th2 and Th1 type of immune responses are pre-
sented in Figure 5 and Figure 6, respectively. In all 
experimental groups the amount of anti-OVA IgG1 antibod-
ies production closely resembled those of total anti-OVA 
IgG levels. Significant decrease of anti-OVA IgG1 antibody 
levels was found in mice immunized with mannosylated lip-
osome formulations with or without immunomodulators in 
comparison to group treated with OVA in saline alone 
(Figure 5). Exception was found for a group of mice 
immunized with antigen and immunomodulators encapsul-
ated into dimannosylated liposomes.  
 Trend of increased anti-OVA IgG2a antibodies pro-
duction in mice immunized with preformed monomanno-
sylated and dimannosylated liposome formulations of OVA 
in comparison to control group of OVA in saline, was found 
(Figure 6 a and 6 c). Experimental group immunized with 
monomannosylated and tetramannosylated liposome for-
mulations of OVA with or without PGM and Ad2TP2 had 
lower anti-OVA IgG2a levels in comparison with group im-
munized with OVA in saline (Figure 6 b and 6 d). This could 
be a result of extremely low entrapment efficiency of OVA. 
However, in the case of tetramannosylated liposomes ad-
dition of Ad2TP2 and even PGM (despite low entrapment 
efficiency) increased anti-OVA IgG2a level in comparison 
with group of mice that received only antigen encapsulated 
in tetramannosylated liposomes (Figure 6 d). 
 The ratio of anti-OVA IgG1/IgG2a levels was calcu-
lated for each serum separately and is presented in a box-
and-whisker plot in Figure 7. A significant difference in anti-
OVA IgG1/IgG2a ratio was found for monomannosylated 
and dimannosylated liposome formulations of OVA in com-
parison to control group of mice received OVA in saline, in-
dicating that mannosylated liposome formulations could 
shift the immune reaction to Th1 type. Addition of immuno-
modulators, PGM and Ad2TP2 into the mannosylated lipo-
somes, reversed anti-OVA IgG1/IgG2a ratio back to mixed 
Th type. The obtained results are in accordance with our 
previous investigations of encapsulation of PGM into con-
ventional PC : CHOL : DCP liposomes and their influence on 
specific immune response.[36] 
 Several research groups have reported synthesis of 
antigen delivery systems that targeted MRs and success-
fully modulate the immune response. Shimizu at al. have 
shown that the administration of soluble leishmanial anti-
gen (SLA) encapsulated in liposomes coated with neoglyco-
lipds containing oligomannose residues, Man5-DPPE and 
Man3-DPPE, induces a specific Th1 immune response in 
mice and protection against Leishmania major infec-
tion.[57,58] Hattori et al. studied potency of mannosylated cat-
ionic liposomes for DNA vaccination using OVA-encoding 
pDNA (pCMV-OVA).[59] They have shown that mannosylated 
cationic liposomes enhanced gene expression of an antigen 
and enhanced Th1 response in comparison to naked pCMV-
OVA and pCMV-OVA complexed with non-mannosylated 
liposomes. The importance of valency and structural fea-
tures of mannose ligands for immunomodulation of specific 
immune response is undeniable but has not yet been 
completely understood. It has been demonstrated that the 
affinity of MRs was enhanced with mannose valencies, 
increasing from 2 to 6 terminal mannose residues in syn-
thesized series of lysine-based cluster oligomannosides.[60] 
Espuelas et al. studied interaction of plain liposomes and 
mannosylated liposomes with immature human dendritic 
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Figure 4. Anti-OVA IgG antibodies levels raised in mice after immunization and two boosters with mannosylated liposome 
formulations of OVA, PGM and Ad2TP2: preformed monomannosylated liposomes (a), monomannosylated liposomes (b), 
dimannosylated liposomes (c), and tetramannosylated liposomes (d). Experimental group: 1. OVA in saline, 2. OVA in 
mannosylated liposomes, 3. (OVA + PGM) in mannosylated liposomes, 4. (OVA + Ad2TP2) in mannosylated liposomes. × group 









Figure 5. Anti-OVA IgG1 antibodies levels raised in mice after immunization and two boosters with mannosylated liposome 
formulations of OVA, PGM and Ad2TP2: preformed monomannosylated liposome (a), monomannosylated liposome (b), 
dimannosylated liposome (c), and tetramannosylated liposome (d). Experimental group: 1. OVA in saline, 2. OVA in manno-
sylated liposomes, 3. (OVA + PGM) in mannosylated liposomes, 4. (OVA + Ad2TP2) in mannosylated liposomes. × group mean 
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Figure 6. Anti-OVA IgG2a antibodies levels raised in mice after immunization and two boosters with mannosylated liposome 
formulations of OVA, PGM and Ad2TP2: preformed monomannosylated liposome (a), monomannosylated liposome (b), 
dimannosylated liposome (c), and tetramannosylated liposome (d). Experimental group: 1. OVA in saline, 2. OVA in manno-
sylated liposomes, 3. (OVA + PGM) in mannosylated liposomes, 4. (OVA + Ad2TP2) in mannosylated liposomes. × group mean 









Figure 7. The ratio of anti-OVA IgG1 and anti-OVA IgG2a levels developed in NIH/OlaHsd (H-2q) mice after immunization and 
two boosters with mannosylated liposome formulations of OVA, PGM and Ad2TP2: preformed monomannosylated liposomes 
(a), monomannosylated liposomes (b), dimannosylated liposomes (c) and tetramannosylated liposomes (d). Experimental 
group: 1. OVA in saline, 2. OVA in mannosylated liposomes, 3. (OVA + PGM) in mannosylated liposomes, 4. (OVA + Ad2TP2) in 
mannosylated liposomes. For each mouse serum, obtained after second booster, log10 (IgG1/IgG2a) was calculated; × group 
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mannosylated lipids incorporated into liposomes were 
more efficiently targeted to iDC than monomannosylated 
lipids.  
 Our results are in accordance with published data 
and we confirmed that in defined conditions for in vivo ex-
periments, dimannosylated liposome formulations were as 
efficient as tetramannosylated liposome formulations. 
Also, we have found that the preformed monomannosyl-
ated liposomes have similar, sometimes even better, effect 
on modulating of specific immune response than mono-
mannosylated liposomes with incorporated monomanno-
syl lipoconjugate. 
 Although the mannosylated liposomal formulations 
of OVA, together with PGM and Ad2TP2 did not show en-
hanced immunostimulation of humoral immune response, 
they significantly affected the type of specific immune re-
action to applied OVA as antigen and directed it towards 
Th1 type. A significant difference in anti-OVA IgG1/IgG2a 
ratios was found for monomannosylated and dimannosyl-
ated liposome formulations of OVA in comparison to con-
trol group of mice receiving OVA in saline. Until now, no 
mannosylated liposomal formulations of OVA together 
with PGM or Ad2TP2 have been described, therefore the 
obtained results are valuble contribution to the develop-
ment of new adjuvants. 
 
CONCLUSIONS 
In this work mannosylated liposome formulations of OVA 
and either PGM or Ad2TP2 were prepared and character-
ized. The liposomes were mannosylated in two ways, by co-
valent attachment of p-aminophenyl-α-D-mannopyranos-
ide to the preformed liposomes and by incorporation of 
synthetic mono-, di- and tetramannosyl-lipoconjugates into 
the lipid bilayer of liposomes. The entrapment efficiency of 
OVA, PGM and Ad2TP2 was calculated and the obtained 
results show that entrapment efficiency is highest in 
monomannosylated preformed liposomes, while in lipo-
somes mannosylated with synthetic mono-, di- and 
tetramannosyl-lipoconjugates it depends on the structure 
and valency of carbohydrate epitope. The lowest entrap-
ment efficiency of OVA was found in monomannosylated 
liposomes. Furthermore, only 6,1 % of Ad2TP2 was encap-
sulated in tetramannosylated liposomes due to steric 
hindrance during the encapsulation. 
 Preliminary in vivo evaluation of adjuvant ability of 
prepared mannosylated liposomes with built-in PGM and 
Ad2TP2, was performed and the influence on production of 
specific anti-OVA IgGs was tested. The specific anti-OVA 
IgG1 and anti-OVA IgG2a, indicators of Th2 and Th1 type of 
immune responses were measured. Significant decrease of 
anti-OVA IgG1 antibody levels was found in mice immun-
ized with liposome formulations both with and without im-
munomodulators in comparison to group treated with 
antigen in saline alone. The ratio of anti-OVA IgG1/IgG2a 
levels was calculated and it reveals that monomannosyl-
ated and dimannosylated liposome formulations of OVA 
significantly decrease this ratio, in comparison to control 
group of mice which received OVA in saline. The results 
demonstrated that mannosylated liposomal formulations 
did not enhance the humoral immune response and pro-
duction of anti-OVA antibodies but they significantly af-
fected the type of OVA specific immune reaction, causing 
polarization to Th1, a cellular type of immune response. 
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